{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:34:43Z","timestamp":1787672083572,"version":"build-2736575974"},"reference-count":0,"publisher":"Jaypee Brothers Medical Publishing","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAPI"],"published-print":{"date-parts":[[2023,4,7]]},"abstract":"<jats:p>Background: Dyspepsia includes a spectrum of symptoms ranging from epigastric pain and early  satiety to postprandial fullness. The worldwide prevalence of dyspepsia is 20\u201330%. It is slightly  higher in the Western population and occurs more frequently among women. While the precise  prevalence of dyspepsia in India is not available, different studies estimate that it affects 7.6\u201349%  of the Indian population. Through our current study, we wanted to understand the demographics,  clinical profile, patient presentation, and management in India. We also wanted to document the  pattern of use of proton pump inhibitors (PPI) and patient satisfaction with PPIs in Indian patients  with dyspepsia. Materials and methods: This pan-India, multi-centric, cross-sectional, questionnaire-based,  noninterventional, observational study was conducted between February and October 2021 in  patients &gt;18 years of age with a clinical diagnosis of any form of dyspepsia. Descriptive statistics  were used for categorical variables, and between-group comparisons were made using Fischer\u2019s  exact test, with p &lt; 0.05 denoting statistical significance. Results: A total of 3,739 patients from across 29 states of India participated in the study. Most of the  patients were male (70.8%) and were from urban areas (56.8%). The highest percentage of patients  were aged 31\u201340 (33.8%), and most patients (60.2%) had dyspepsia for a duration of 6\u201312 months.  Patients with functional dyspepsia (FD) (78.5%) were significantly higher compared to organic  dyspepsia (OD) (21.5%) (p &lt; 0.001). The most frequent presenting symptoms were epigastric pain,  nausea, vomiting, and heartburn. A quarter (25.6%) of the dyspepsia patients were associated  with various comorbid conditions, of which diabetes mellitus, hypertension, and irritable bowel  syndrome are the most common ones. A total of 619 patients in the study were on concomitant  medications, of which the most common were antidiabetic drugs (271\/619, 43.8%). Rabeprazole  was the most frequently used PPI (2467\/3739, 66.0%) among the study participants. The patient  satisfaction analysis showed that, overall, patients were satisfied with PPIs, as most patients  (~80%) agreed to almost all questions. The analysis for individual PPIs showed the highest \u201cagree\u201d  responses in the rabeprazole group for almost all questions (12 of 13). Around 86.4% of patients  on rabeprazole agreed with \u201cimmediate relief from acidity,\u201d 84.9% for \u201cgives me complete relief,\u201d  and 85.9% for \u201crelief from nighttime acidity symptoms.\u201d Conclusion: Our study involving over 3,700 Indian patients with Dyspepsia adds to the growing  knowledge of dyspepsia in India. Dyspepsia is more prevalent in males and in the 31\u201350 age group.  FD is the most common form. Overall, patients were satisfied with PPIs in dyspepsia management  in India. Patients on rabeprazole showed higher levels of medication adherence, satisfaction with  symptom relief, convenience of therapy, and safety compared to patients on other PPIs. Against  the backdrop of a paucity of reliable data about dyspepsia in India, our study results provide  valuable insights into Dyspepsia and its management in an Indian setting.<\/jats:p>","DOI":"10.5005\/japi-11001-0231","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T05:21:00Z","timestamp":1685596860000},"page":"36-46","source":"Crossref","is-referenced-by-count":4,"title":["Dyspepsia - The Indian perspective: A cross sectional study on  demographics and treatment patterns of Dyspepsia from across  India (Power 1.0 study)"],"prefix":"10.59556","volume":"71","author":[{"given":"Randhir","family":"Sud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kranthi Kiran","family":"Pebbili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank Ashit","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amey","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Kotak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","published-online":{"date-parts":[[2023,4,1]]},"container-title":["Journal of the Association of Physicians of India"],"original-title":[],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:57:28Z","timestamp":1745578648000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/files\/JAPI0231_p36-46_compressed.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":0,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2023,4,1]]},"published-print":{"date-parts":[[2023,4,7]]}},"URL":"https:\/\/doi.org\/10.5005\/japi-11001-0231","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}